Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-Negative Early Breast Cancer

How do you define high-risk for recurrence in breast cancer?

Credit available for this activity expires: [03/27/25] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000352?ecd=bdc_podcast_libsyn_mscpedu